Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta‐analysis

@article{Mills2005MelatoninIT,
  title={Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta‐analysis},
  author={Edward J. Mills and Ping Wu and Dugald Seely and Gordon H. Guyatt},
  journal={Journal of Pineal Research},
  year={2005},
  volume={39}
}
Most observational studies show an association between melatonin and cancer in humans. [] Key Method With the aid of an information specialist, we searched 10 electronic databases from inception to October 2004. We included trials using melatonin as either sole treatment or as adjunct treatment. Prespecified criteria guided our assessment of trial quality. We conducted a meta-analysis using a random effects model. We included 10 RCTs published between 1992 and 2003 and included 643 patients.
Safety of higher doses of melatonin in adults: A systematic review and meta‐analysis
TLDR
Based on this limited evidence, melatonin appears to have a good safety profile and better safety reporting in future long-term trials is needed to confirm this as the confidence limits were very wide due to the paucity of suitable data.
Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial.
TLDR
Melatonin in combination with chemotherapy did not affect survival and adverse events of advanced patients with NSCLC, but there was a trend for better HRQoL, implying the protective effect of melatonin in healthy cells.
Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action
TLDR
Melatonin has been shown to be associated with a wide variety of health outcomes in clinically and methodologically heterogeneous populations and many reviews stressed the need for more high-quality randomised clinical trials to reduce the existing uncertainties.
Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review
TLDR
There are insufficient robust data to allow a meaningful appraisal of concerns that melatonin may result in more clinically significant adverse effects in potentially at-risk populations, and the scarcity of evidence from long-term RCTs limits the conclusions regarding the safety of continuous melatonin therapy over extended periods.
Melatonin for the treatment of dementia
TLDR
The analyses did not support the use of melatonin for treatment of cognitive impairment associated with dementia, and meta-analysis of psychopathologic behavior scale scores suggested that melatonin may be effective in treating these dementia-related disturbances.
A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers
TLDR
Overall, among postmenopausal women with a prior history of breast cancer, a 4-month course of 3 mg melatonin daily did not influence circulating estradiol, IGF-1, or IGFBP-3 levels, and compliance was comparable between the two groups.
Effects of Melatonin on Quality of Life of Non-resectable Cholangiocarcinoma Patients
TLDR
The combination of melatonin with standard treatment did not prolong overall survival period and the melatonin treatment, however,decreased adverse events and maintained QOL of non-resectable cholangiocarcinoma patients.
Melatonin as Adjuvant Cancer Care With and Without Chemotherapy
TLDR
Melatonin may benefit cancer patients who are also receiving chemotherapy, radiotherapy, supportive therapy, or palliative therapy by improving survival and ameliorating the side effects of chemotherapy.
The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature
TLDR
Melatonin has been observed to suppress the growth of cancer cells, inhibit metastatic spread, enhance immune system functions, and act as an anti-inflammatory in both in vitro and in vivo models and there may be potential for the use of melatonin as an adjuvant oncostatic treatment.
...
...

References

SHOWING 1-10 OF 43 REFERENCES
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma
TLDR
This preliminary study suggests that an adjuvant endocrine therapy with melatonin may be effective in preventing disease progression in node‐relapsed melanoma patients.
Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group
TLDR
The reporting of methodological aspects of randomised controlled trials does not necessarily reflect the conduct of the trial and reviewing research protocols and contacting trialists for more information may improve quality assessment.
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
TLDR
This randomized study shows that the pineal hormone MLT may be successfully administered to prolong the survival time in metastatic NSC lung cancer patients who progressed under a first-line chemotherapy with cisplatin, for whom no other effective therapy is available up to now.
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
TLDR
The neuroendocrine combination with TMX plus MLT may have some benefit in untreatable metastatic solid tumour patients, either in controlling cancer cell proliferation or improving the PS.
A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients.
TLDR
This preliminary study suggests that the association of the pineal hormone MLT may make TMX effective also in ER-negative metastatic breast cancer patients.
Five years survival in metastatic non‐small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial
TLDR
Assessment of the 5‐year survival results in metastatic non‐small cell lung cancer patients obtained with a chemotherapeutic regimen consisting of cisplatin and etoposide, with or without the concomitant administration of melatonin suggests a new biochemotherAPEutic strategy in the treatment of human neoplasms.
Is there a role for melatonin in supportive care?
  • P. Lissoni
  • Medicine, Biology
    Supportive Care in Cancer
  • 2002
TLDR
The present clinical results demonstrate that the pineal hormone MLT may be successfully administered in medical oncology in the supportive care of untreatable advanced cancer patients and for the prevention of chemotherapy-induced toxicity.
A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first‐line treatment of advanced non‐small cell lung cancer patients in a poor clinical state
TLDR
It is shown that the concomitant administration of melatonin may improve the efficacy of chemotherapy, mainly in terms of survival time, and reduce chemotherapeutic toxicity in advanced NSCLC, at least in patients in poor clinical condition.
[Safety in melatonin use].
TLDR
The adverse effects to MLT consumption in humans is reviewed, finding that this product is not harmless for health and attention should be paid on the necessity of enquiring about the drugs that patients are taking.
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.
TLDR
It is suggested that a radioneuroendocrine approach with RT plus the pineal hormone MLT may prolong the survival time and improve the quality of life of patients affected by glioblastoma.
...
...